




RealRate

PHARMACEUTICAL 2018

Seres Therapeutics Inc. Rank 239 of 342





RealRate

PHARMACEUTICAL 2018

Seres Therapeutics Inc.
Rank 239 of 342



The relative strengths and weaknesses of Seres Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Seres Therapeutics Inc. compared to the market average is the variable Property and Equipment, increasing the Economic Capital Ratio by 25% points. The greatest weakness of Seres Therapeutics Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 104% points.

The company's Economic Capital Ratio, given in the ranking table, is 9.4%, being 36% points below the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	155,078
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	31,625
Liabilities, Non-Current	1,129
Other Assets	1,513
Other Compr. Net Income	3.0
Other Expenses	0
Other Liabilities	96,069
Other Net Income	2,015
Other Revenues	32,100
Property and Equipment	32,931
Research and Development	89,455
Selling, General and Administrative Expense	34,040

Output Variable	Value in 1000 USD
Assets	189,522
Liabilities	128,823
Expenses	123,495
Revenues	32,100
Stockholders Equity	60,699
Net Income	-89,380
Comprehensive Net Income	-89,378
Economic Capital Ratio	9.4%